[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100512600":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":30,"locations":35,"responsibleParty":66,"collaborators":68,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":24,"eligibilityCriteria":77,"healthyVolunteers":78,"sex":79,"minAge":80,"maxAge":24,"enrollmentInfo":81,"targetDuration":24,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":24,"overallStatus":38,"whyStopped":24,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Johns Hopkins University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"0.05 mmol\u002Fkg Elucirem","EXPERIMENTAL","a group that receives 0.05 mmol\u002Fkg Elucirem",[13],"Drug: Elucirem (Gadopiclenol)",{"label":15,"type":10,"description":16,"interventionNames":17},"0.075 mmol\u002Fkg Elucirem","A group that receives 0.075 mmol\u002Fkg Elucirem",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Elucirem (Gadopiclenol)","Elucirem (Gadopiclenol) is a new macrocyclic gadolinium-based contrast agent (GBCA) with high relaxivity indicated for use in adults and children aged 2 years and older for contrast-enhanced magnetic resonance imaging.",[9,15],null,[26],{"name":27,"affiliation":28,"role":29},"Joao Lima, Professor","MD","PRINCIPAL_INVESTIGATOR",[31],{"name":27,"role":32,"phone":33,"phoneExt":24,"email":34},"CONTACT","4106141284","jlima@jhmi.edu",[36,55],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Johns Hopkins Center for Advanced Imaging and Research Science, located in the Science + Technology Park at 1812 Ashland Avenue, Baltimore, MD.","RECRUITING","Baltimore","Maryland","21202","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-76.61219,39.29038,{"lat":48,"lon":47},[51],{"name":52,"role":32,"phone":53,"phoneExt":24,"email":54},"Aysa Ostovaneh","410-458-0198","aostova2@jh.edu",{"facility":56,"status":57,"city":39,"state":40,"zip":58,"country":42,"countryCode":43,"cosmosGeoPoint":59,"geoPoint":61,"contacts":62},"Johns Hopkins School of Medicine","NOT_YET_RECRUITING","21205",{"type":45,"coordinates":60},[47,48],{"lat":48,"lon":47},[63],{"name":64,"role":32,"phone":24,"phoneExt":24,"email":65},"Michelle Hughes-Lukoski","mhughe17@jh.edu",{"type":67,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR",[69],{"name":70,"class":71},"Guerbet","INDUSTRY","100512600","phase-4-high-relaxivity-contrast-agent-for-cardiac-mr-in-the-myocardial-scar-assessment-100512600",false,"NCT05954559","High Relaxivity Contrast Agent for Cardiac MR in the Myocardial Scar Assessment","Inclusion Criteria:\n\n* Participants from previous double-dose Doatrem CMR study who are willing to participate and sign the consent will be enrolled in this study. Participants must be ≥21 years old, less than 120kg, not claustrophobic, and eGFR be 60 and more.\n\nExclusion Criteria:\n\n* Participants under 21 years old will be excluded. Contraindications or limitations to contrast-enhanced MRI such as self-report of kidney disease, including kidney transplant or kidney surgery, eGFR less than 60, Metal fragments in eyes, brain, or spinal cord, Internal electrical devices such as cochlear implant, spinal cord stimulator, pacemaker, or defibrillator, pregnancy, allergic reaction to gadolinium in the past, claustrophobia, and cardiogenic shock or unstable condition that cannot tolerate the MRI scan will be excluded.",true,"ALL","21 Years",{"count":82,"type":83},25,"ESTIMATED","INTERVENTIONAL",[86],"PHASE4","Elucirem (Gadopiclenol) is a new macrocyclic gadolinium-based contrast agent (GBCA) with high relaxivity indicated for use in adults and children aged 2 years and older for contrast-enhanced magnetic resonance imaging. The product was approved in 2022 by FDA to be used to detect and visualize lesions with abnormal vascularity in the central nervous system (brain, spine and associated tissues) and the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system). However, given its at least twofold higher relaxivity than other GBCAs, the performance of Elucirem in cardiac MR (CMR) has yet to be demonstrated.\n\nThe hypothesis for the study: Half dose (0.05mmol\u002Fkg) Elucirem is not inferior to double dose (0.2 mmol\u002Fkg) Dotarem in the myocardial scar assessment.\n\nAll participants will be selected from the investigators previous CMR study cohort with double-dose Dotarem T1 mapping and LGE images. Ten participants without scars will be recruited for the Phase I dose evaluation. Five for 0.05 mmol\u002Fkg and five for 0.075 mmol\u002Fkg. The investigators have identified 15 participants with LGE findings from double-dose Dotarem CMR acquired in the years 2021, 2022, or earlier years. This study was performed in August 2022. The same protocol will be used for single-dose Elucirem.",[89],"Myocardial Fibrosis","2026-04-08",{"date":92,"type":93},"2026-04-13","ACTUAL",{"date":95,"type":93},"2025-08-01",{"date":97,"type":83},"2026-12",{"name":5,"class":6},2]